Marker Therapeutics, Inc. revenue by segment MRKR

Annual Quarterly

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Revenue	4	—	1	1	1	1	0	2	2
Grant	—	—	—	1 -51.0% share 100.0%	1 -36.0% share 100.0%	1 share 100.0%	—	2 share 100.0%	2 share 100.0%
Cprit Pancreatic Grant	—	—	0 +1906.2% share 33.5%	—	—	—	0 share 3.6%	—	—
Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia	—	—	0 -4.2% share 27.7%	—	—	—	0 share 62.3%	—	—
Cprit Grant	—	—	—	—	0 share 16.2%	—	—	—	—
National Institutes Of Health Small Business Innovation Research	—	—	0 +20.4% share 15.5%	0 share 15.6%	0 share 16.2%	0 share 1.4%	0 share 27.7%	—	—
National Institutes Of Health National Cancer Institute Grant	—	—	0 +593.8% share 13.1%	0 share 8.3%	0 share 8.1%	—	0 share 4.1%	—	—
National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer	—	—	0 +820.9% share 9.8%	—	0 share 16.2%	0 share 11.6%	0 share 2.3%	—	—
Additional Cprit Grant	—	—	—	—	—	—	0 share 3.7%	—	—
Fda Grant	—	—	0 share 0.4%	0 share 1.7%	0 share 0.8%	0 share 11.6%	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: MRKR (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Houston, TX
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1094038
Former names: TAPIMMUNE INC. (until Oct 17, 2018); TAPIMMUNE INC (until Jun 29, 2017); GENEMAX CORP (until Jun 28, 2007); EDUVERSE COM (until Jun 17, 2002)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.